

**MEDICAL POLICY – 7.01.133****Microwave Tumor Ablation**

BCBSA Ref. Policy: 7.01.133


Effective Date: Jan. 1, 2025  
Last Revised: Dec. 9, 2024  
Replaces: N/A

**RELATED MEDICAL POLICIES:**

7.01.92	Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Prostate, or Dermatologic Tumors
7.01.95	Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors
8.01.11	Transcatheter Arterial Chemoembolization as a Treatment for Primary or Metastatic Liver Malignancies
8.01.521	Radioembolization for Primary and Metastatic Tumors of the Liver

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)  
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

## Introduction

Ablation refers to destroying tumors without removing them. Microwave ablation is a method of treating tumors using microwave energy. A small probe is placed into the tumor. The probe sends out microwave energy. The microwaves cause enough heat to kill tumor cells. Medical studies show that while this technique can destroy tumors at a particular location, cancer recurrence at other sites is common, depending on the stage and type of cancer. This policy describes when microwave ablation of tumors may be considered medically necessary.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

## Policy Coverage Criteria

**Note: Radiofrequency ablation of primary or metastatic liver tumors is considered standard treatment and does not require medical necessity review**

Service	Medically Necessary
<p><b>Microwave ablation (MWA), primary or metastatic hepatic tumors</b></p>	<p><b>Microwave ablation (MWA) of primary or metastatic hepatic tumors may be considered medically necessary under the following conditions:</b></p> <ul style="list-style-type: none"> <li>• The tumor is unresectable due to location of lesion(s)</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• The individual has a comorbid condition(s) that is contraindicative to surgery</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• A single tumor of less than or equal to 5 cm in size</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• 3 or fewer nodules of less than or equal to 3 cm each in size</li> </ul>
<p><b>MWA, primary or metastatic lung tumors</b></p>	<p><b>MWA of primary or metastatic lung tumors may be considered medically necessary under the following conditions:</b></p> <ul style="list-style-type: none"> <li>• The tumor is unresectable due to location of lesion(s)</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• The individual has a comorbid condition(s) that is contraindicative to surgery</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• A single tumor of less than or equal to 3 cm in size</li> </ul>

Service	Investigational
<p><b>MWA</b></p>	<p><b>MWA of more than one single primary or metastatic tumor in the lung is considered investigational.</b></p> <p><b>MWA of primary or metastatic tumors other than liver or lung is considered investigational.</b></p>

Documentation Requirements
<p><b>The individual’s medical records submitted for review should document that medical necessity criteria are met. The record should include the following:</b></p>



## Documentation Requirements

- Office visit notes that contain the relevant history and physical demonstrating tumor type, indicating that the tumor is unresectable with the rationale why the tumor is unresectable, and the size of the tumor(s).

## Coding

According to an American Medical Association publication (Clinical Examples in Radiology, 2012, 8, [3;]), "microwave is part of the radiofrequency spectrum, and simply uses a different part of the radiofrequency spectrum to develop heat energy to destroy abnormal tissue." Therefore, the American Medical Association recommends that microwave ablation be reported using CPT codes for radiofrequency ablation as noted in the coding table below.

Code	Description
<b>CPT</b>	
0944T	3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation (new code effective 1/01/2025)
32998	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, radiofrequency, unilateral
47382	Ablation, 1 or more liver tumor(s), percutaneous, radiofrequency
50592	Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency
60699	Unlisted procedure, endocrine system (for adrenal or thyroid tumors)
<b>HCPCS</b>	
C9751	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information



This policy does not address microwave ablation (MWA) for the treatment of splenomegaly, ulcers, for cardiac applications, or as a surgical coagulation tool.

## Evidence Review

---

### Description

Microwave ablation (MWA) is a technique to destroy tumors and soft tissue using microwave energy to create thermal coagulation and localized tissue necrosis. MWA is used to treat tumors not amenable to resection and to treat individuals that are ineligible for surgery due to age, comorbidities, or poor general health. MWA may be performed as an open procedure, laparoscopically, percutaneously, or thoracoscopically under image guidance (e.g., ultrasound, computed tomography, magnetic resonance imaging) with sedation, or local or general anesthesia. This technique is also referred to as microwave coagulation therapy.

### Background

#### Microwave Ablation

MWA uses microwave energy to induce an ultra-high speed, 915 MHz or 2.450 MHz (2.45 GHz), alternating electric field, which causes water molecule rotation and creates heat. This results in thermal coagulation and localized tissue necrosis. In MWA, a single microwave antenna or multiple antennas connected to a generator are inserted directly into the tumor or tissue to be ablated; energy from the antennas generates friction and heat. The local heat coagulates the tissue adjacent to the probe, resulting in a small, 2 cm to 3 cm elliptical area of tissue ablation. In tumors greater than 2 cm in diameter, two to three antennas may be used simultaneously to increase the targeted area of MWA and shorten operative time. Multiple antennas may also be used simultaneously to ablate multiple tumors. Tissue ablation occurs quickly, within one minute after a pulse of energy, and multiple pulses may be delivered within a treatment session, depending on tumor size. The cells killed by MWA are typically not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the margins. Treatment may be repeated as needed. MWA may be used for the following purposes:



1. Control local tumor growth and prevent recurrence
2. Palliate symptoms
3. Prolong survival

MWA is similar to radiofrequency (RFA) and cryosurgical ablation. However, MWA has potential advantages over RFA and cryosurgical ablation. In MWA, the heating process is active, which produces higher temperatures than the passive heating of RFA and should allow for more complete thermal ablation in less time. The higher temperatures reached with MWA (>100°C) can overcome the “heat sink” effect in which tissue cooling occurs from nearby blood flow in large vessels, potentially resulting in incomplete tumor ablation. MWA does not rely on the conduction of electricity for heating and, therefore, does not flow electrical current through individuals and does not require grounding pads, because there is no risk of skin burns. Additionally, MWA does not produce electric noise, which allows ultrasound guidance during the procedure without interference, unlike RFA. Finally, MWA can take 20% to 30% less time than RFA because multiple antennas can be used simultaneously for multiple ablations. There is no comparable RFA system with the capacity to drive multiple electrically dependent electrodes.

### **Adverse Events**

Complications from MWA may include pain and fever. Other complications associated with MWA include those caused by heat damage to normal tissue adjacent to the tumor (e.g., intestinal damage during MWA of the kidney or liver), structural damage along the probe track (e.g., pneumothorax as a consequence of procedures on the lung), liver enzyme elevation, liver abscess, ascites, pleural effusion, diaphragm injury or secondary tumors if cells seed during probe removal. MWA should be avoided in pregnant women because potential risks to the individual and/or fetus have not been established, and in individuals with implanted electronic devices (e.g., implantable pacemakers) that may be adversely affected by microwave power output.

### **Applications**

MWA was first used percutaneously in 1986 as an adjunct to liver biopsy. Since then, MWA has been used to ablate tumors and tissue to treat many conditions including hepatocellular carcinoma, breast cancer, colorectal cancer metastatic to the liver, renal cell carcinoma, renal hamartoma, adrenal malignant carcinoma, non-small-cell lung cancer, intrahepatic primary cholangiocarcinoma, secondary splenomegaly and hypersplenism, abdominal tumors, and other



tumors not amenable to resection. Well-established local or systemic treatment alternatives are available for each of these malignancies. The potential advantages of MWA for these cancers include improved local control and other advantages common to any minimally invasive procedure (e.g., preserving normal organ tissue, decreasing morbidity, shortening length of hospitalization). MWA also has been investigated as treatment for unresectable hepatic tumors, as both primary and palliative treatment, and as a bridge to a liver transplant. In the latter setting, MWA is being assessed to determine whether it can reduce the incidence of tumor progression while awaiting transplantation and thus maintain an individual's candidacy while awaiting a liver transplant.

## Summary of Evidence

For individuals who have an unresectable primary or metastatic hepatic tumor who receive MWA, the evidence includes randomized controlled trials (RCTs), comparative observational studies, and systematic reviews comparing MWA to RFA and to surgical resection. The relevant outcomes are overall survival OS, disease-specific survival, symptoms, quality of life (QOL), and treatment-related mortality and morbidity. The body of evidence indicates that MWA is an effective option in individuals for whom resection is not an option. Although studies had methodological limitations, results consistently showed that MWA and RFA had similar survival outcomes with up to five years of follow-up in individuals with a single tumor  $\leq 5$  cm or up to three nodules  $\leq 3$  cm each. In meta-analyses of observational studies, individuals receiving MWA had higher local recurrence rates and lower survival than those who received resection, but the individual populations were not limited to those who had unresectable tumors. MWA was associated with lower complications, intraoperative blood loss, and hospital length of stay. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an unresectable primary or metastatic lung tumor who receive MWA, the evidence includes one RCT, retrospective observational studies, and systematic reviews of these studies. The relevant outcomes are OS, disease-specific survival, symptoms, QOL, and treatment-related mortality and morbidity. The body of evidence indicates that MWA is an effective option in individuals for whom resection is not an option. In the RCT, direct comparison of MWA and RFA in individuals with primary or metastatic lung cancer (mean tumor size 1.90 cm [ $\pm 0.89$ ] at baseline) found similar mortality rates up to 12 months of follow-up. In the first of three systematic reviews that included 12 retrospective observational studies, local recurrence rates were similar for MWA and RFA at a range of 9 to 47 months of follow-up. In the second systematic review with a meta-analysis, there was lower OS with MWA compared to RFA, but



studies were not directly comparable due to clinical and methodological heterogeneity. However, the authors concluded that percutaneous RFA and MWA were both effective with a high safety profile. In the third systematic review using a network meta-analysis, the weighted average OS rates for MWA were 82.5%, 54.6%, 35.7%, 29.6%, and 16.6% at 1, 2, 3, 4, and 5 years, respectively. Limitations of the body of evidence included a lack of controlled studies and heterogeneity across studies. The RCT did not report results by tumor size or the number of metastases. The observational studies included in the systematic reviews did not report sufficient information to assess the effectiveness or safety of MWA in subgroups based on the presence of multiple tumors or total tumor burden. Therefore, conclusions about the evidence sufficiency can only be made about individuals with single tumors. For this population, the evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an unresectable primary or metastatic renal tumor who receive MWA, the evidence includes one RCT that compared MWA to partial nephrectomy, retrospective reviews, systematic reviews and meta-analyses of the retrospective reviews (with or without the single RCT) and case series. The relevant outcomes are OS, disease-specific survival, symptoms, QOL, and treatment-related mortality and morbidity. In the RCT, overall local recurrence-free survival at 3 years was 91.3% for MWA and 96.0% for partial nephrectomy ( $p=0.54$ ). This positive outcome should be replicated in additional RCTs. There are also no controlled studies comparing MWA to other ablation techniques in individuals with renal tumors. The evidence is insufficient to determine that the technology results in an improvement in the health outcome.

For individuals who have unresectable primary or metastatic solid tumors other than hepatic, lung, or renal who receive MWA, the evidence includes systematic reviews and case series. No RCTs on the use of MWA for other tumors or conditions were identified. The relevant outcomes are OS, disease-specific survival, symptoms, quality of life, and treatment-related mortality and morbidity. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in [Table 1](#).



**Table 1. Summary of Key Trials**

<b>NCT No.</b>	<b>Trial Name</b>	<b>Planned Enrollment</b>	<b>Completion Date</b>
<b>Ongoing</b>			
<b>NCT04081168</b>	COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation (COLLISION-XL)	68	Jan 2025
<b>NCT03775980<sup>a</sup></b>	CIRSE Emprint Microwave Ablation Registry (CIEMAR)	500	Jan 2026
<b>NCT04365751</b>	To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma	1134	Dec 2026
<b>NCT04107766<sup>a</sup></b>	NeuWave Observational Liver Ablation Registry (NOLA)	1500	Dec 2027

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## Clinical Input from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

### 2016 Input

In response to requests, input was received from two physician specialty societies and one academic medical center while this policy was under review in 2016. This number of responses was less than optimal. Input overall was mixed. There was some support for the medical necessity of MWA in each category, with some reviewers indicating that it was standard of care for certain tumors. However, there were no indications for which all three reviewers agreed that MWA should be medically necessary.





## 2011 Input

In response to requests, input was received from two physician specialty societies (three reviews) and four academic medical centers (six reviews) while this policy was in development. Eight reviewers considered MWA investigational to treat primary tumors such as hepatocellular carcinoma, benign and malignant renal tumors, lung tumors, adrenal tumors, or cholangiocarcinoma. The reviewers noted insufficient evidence and a need for further studies on MWA. However, one reviewer indicated MWA for primary tumors, including, but not limited to, hepatocellular carcinoma, benign and malignant renal tumors, lung tumors, adrenal tumors and cholangiocarcinoma, may be considered a treatment option, and another reviewer indicated that MWA for renal tumors may be considered a treatment option.

Four reviewers considered MWA investigational to treat liver metastases, and two reviewers indicated MWA for liver metastases may be considered a treatment option. One reviewer noted MWA may be appropriate for tumors not amenable to RFA or other local treatments. This reviewer also suggested MWA may be more appropriate for tumors located near large blood vessels.

## Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the policy conclusions.

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a US professional society, an international society with US representation, or the National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

## American College of Chest Physicians

The American College of Chest Physicians (2013) evidence-based guidelines on the treatment of non-small-cell lung cancer (NSCLC) noted that the role of ablative therapies in the treatment of high-risk patients with stage I NSCLC is evolving.<sup>110</sup> The guidelines deal mostly with RFA.



## American Urological Association

The American Urological Association (2021) updated its guidelines on renal mass and localized renal cancer, which note that both RFA and cryoablation may be offered as options for individuals who elect thermal ablation (Conditional Recommendation; Evidence Level: Grade C).<sup>111</sup> Thermal ablation can be considered as an alternate approach in the management of T1a solid renal masses <3 cm. In these individuals, a percutaneous technique is preferred (Moderate Recommendation; Evidence Level: Grade C). The guidelines do not specifically address MWA.

## National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) guidelines on hepatocellular carcinoma (HCC) (v.2.2024) list MWA (along with RFA, cryoablation, and percutaneous alcohol injection) as a treatment option for HCC tumors in individuals who are not candidates for potential curative treatments (e.g., resection and transplantation) and do not have large-volume extrahepatic disease.<sup>112</sup> Ablation should only be considered when tumors are accessible by percutaneous, laparoscopic, or open approaches. The guidelines indicate "Ablation alone may be curative in treating tumors less than or equal to 3 cm [...] Lesions 3 to 5 cm may be treated to prolong survival using arterially directed therapies, or with combination of an arterially directed therapy and ablation as long as tumor location is accessible for ablation."

The guidelines on NSCLC (v.7.2024) state that image-guided thermal ablation therapies such as cryotherapy, microwave, or radiofrequency may be an option for select medically inoperable individuals not receiving stereotactic ablative radiotherapy or definitive radiotherapy.<sup>113</sup> Image-guided thermal ablation therapy is considered an option for the management of NSCLC lesions <3 cm as ablation for NSCLC lesions >3 cm has been associated with higher rates of local recurrence and complications.

Guidelines on small-cell lung cancer (v.3.2024) state, "stereotactic ablative radiotherapy is an option for certain patients with medically inoperable stage I to IIA small-cell lung cancer."<sup>114</sup>

The Network guidelines on neuroendocrine tumors, (v.2.2024) state that cytoreductive surgery or ablative therapies (i.e. radiofrequency, cryotherapy, microwave) may be considered in individuals with progressive hepatic-predominant metastatic disease to reduce tumor bulk and relieve symptoms of hormone hypersecretion (category 2B). Additionally, although prospective data for ablative therapy interventions are limited, the guideline notes that "percutaneous thermal ablation, often using microwave energy, can be considered for oligometastatic liver disease, generally up to four lesions each smaller than 3 cm."<sup>115</sup>



The guidelines on kidney cancer (v.1.2025) state that thermal ablation techniques (MWA, RFA and cryotherapy) may be an option for T1 renal lesions, particularly for masses <3 cm.<sup>116</sup>

The guidelines on breast cancer (v.4.2024) do not address thermal ablation techniques such as MWA.<sup>117</sup>

Thyroid cancer guidelines from NCCN (v.3.2024) recommend ablation techniques such as cryoablation or RFA as an option for metastatic disease in select patients.<sup>118</sup> There is no specific mention of MWA.

## National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (NICE) (2016) updated its guidance on MWA for treatment of metastases in the liver.<sup>119</sup> The revised guidance states:

- Current evidence on MWA for treating liver metastases raises no major safety concerns and the evidence on efficacy is adequate in terms of tumor ablation. Therefore, this procedure may be used provided that standard arrangements are in place for clinical governance, consent, and audit.
- Patient selection should be carried out by a hepatobiliary cancer multidisciplinary team.
- Further research would be useful for guiding the selection of individuals for this procedure. This should document the site and type of the primary tumor being treated, the intention of treatment (palliative or curative), imaging techniques used to assess the efficacy of the procedure, long-term outcomes and survival.

The Institute (2007) also published guidance on MWA for HCC.<sup>120</sup> This guidance indicated: "Current evidence on the safety and efficacy of MWA of hepatocellular carcinoma appears adequate to support the use of this procedure..." The guidance also stated there are no major concerns about the efficacy of MWA, but noted that limited, long-term survival data are available.

The Institute (2022) has published guidance on MWA for lung tumors as well.<sup>121</sup> This guidance indicated that, "Evidence on the safety of microwave ablation for treating primary lung cancer and metastases in the lung is adequate but shows it can cause infrequent serious complications. Evidence on its efficacy shows it reduces tumor size. But the evidence on improvement in survival, long-term outcomes and quality of life is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. " The guidance encourages further research.



## Society of American Gastrointestinal and Endoscopic Surgeons

In 2023, the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and the Americas Hepato-Pancreato-Biliary Association (AHPBA) published guidelines for the use of MWA and RFA for the treatment of HCC.<sup>122</sup> The panel recommended that MWA or RFA can be utilized in patients with HCC and colorectal liver metastases. However, they did note that available evidence was poor quality and treatment decisions should be individualized.

## Medicare National Coverage

There is no national coverage determination.

## Regulatory Status

Multiple MWA devices have been cleared for marketing by the US Food and Drug Administration (FDA) through the 510(k) process. These devices are indicated for soft tissue ablation, including partial or complete ablation of nonresectable liver tumors. Some devices are specifically cleared for use in open surgical ablation, percutaneous ablation or laparoscopic procedures. **Table 2** is a summary of selected MWA devices cleared by the FDA.

The FDA used determinations of substantial equivalence to existing radiofrequency and MWA devices to clear these devices. FDA product code: NEY.

This policy does not address MWA for the treatment of splenomegaly or ulcers, for cardiac applications, or as a surgical coagulation tool.

**Table 2. Selected MWA Devices Cleared by FDA**

Device	Indication	Manufacturer	Date Cleared	510(k) No.
MedWaves Microwave Coagulation/Ablation System	General surgery use in open procedures for the coagulation and ablation of soft tissues	MedWaves Incorporated	12/2007	K070356



Device	Indication	Manufacturer	Date Cleared	510(k) No.
Acculis Accu2i pMTA Microwave Tissue Ablation Applicator  Acculis Accu2i pMTA Applicator and SulisV pMTA Generator	Intraoperative coagulation of soft tissue  Software addition	Microsoulis Holdings, Ltd	8/2010  11/2012	K094021  K122762
MicroThermX Microwave Ablation System	Coagulation (ablation) of soft tissue. May be used in open surgical as well as percutaneous ablation procedures.	BSD Medical Corporation	8/2010	K100786
Emprint Ablation System  Emprint Ablation System  Emprint SX Ablation Platform with Thermosphere Technology  Emprint Ablation Platform with Thermosphere Technology and Emprint SX Ablation Platform with Thermosphere Technology	Percutaneous, laparoscopic, and intraoperative coagulation (ablation) of soft tissue, including partial or complete ablation of non-resectable liver tumors.  Same with design modification of device antenna for percutaneous use  3-D navigation feature assists in the placement of antenna using real-time image guidance during intraoperative and laparoscopic ablation procedures.  Antenna modification and update to instructions for use	Medtronic	4/2014  12/2016  9/2017  2/2020	K133821  K163105  K171358  K193232
Certus 140 2.45 GHz Ablation System and Accessories  Certus 140 2.45 GHz Ablation System and Accessories  CertuSurg Surgical Tool  Certus 140 2.45 GHz Ablation System and Accessories  Certus 140 2.45GHz Ablation System	Ablation (coagulation) of soft tissue.  Ablation (coagulation) of soft tissue in percutaneous, open surgical and in conjunction with laparoscopic surgical settings.  Surgical coagulation (including Planar Coagulation) in open surgical settings.	Johnson & Johnson	10/2010  01/2012  7/2013  5/2016  10/2018	K100744  K113237  K130399  K160936  K173756



Device	Indication	Manufacturer	Date Cleared	510(k) No.
	Same indication with probe redesign  Ablation (coagulation) of soft tissue in percutaneous, open surgical and in conjunction with laparoscopic surgical settings, including the partial or complete ablation of non-resectable liver tumors.			
NEUWAVE Flex Microwave Ablation System (FLEX)	Ablation (coagulation) of soft tissue.  Design evolution of Certus 140 2.45GHz Ablation System (K160936)	Johnson & Johnson	3/2017	K163118
Solero Microwave Tissue Ablation (MTA) System and Accessories	Ablation of soft tissue during open procedures	Angiodynamics, Inc.	5/2017	K162449
Microwave Ablation System	Coagulation (ablation) of soft tissue	Surgnova Healthcare Technologies (Zhejiang) Co., Ltd	7/2019	K183153
NEUWAVE Microwave Ablation System and Accessories	Ablation (coagulation) of soft tissue in percutaneous, open surgical and in conjunction with laparoscopic surgical settings, including the partial or complete ablation of non-resectable liver tumors; not intended for use in cardiac procedures.	Johnson & Johnson	11/2020	K200081
IntelliBlate Microwave Ablation System	Coagulation (ablation) of soft tissue	Varian Medical Systems, Inc	7/2024	K240480

FDA: Food and Drug Administration.

## References

- Chinnaratha MA, Chuang MY, Fraser RJ, et al. Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. Feb 2016; 31(2): 294-301. PMID 26114968



2. Bertot LC, Sato M, Tateishi R, et al. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. *Eur Radiol.* Dec 2011; 21(12): 2584-96. PMID 21858539
3. Ong SL, Gravante G, Metcalfe MS, et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review. *Eur J Gastroenterol Hepatol.* Jun 2009; 21(6): 599-605. PMID 19282763
4. Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. *World J Surg Oncol.* Jun 10 2019; 17(1): 98. PMID 31182102
5. Cui R, Yu J, Kuang M, et al. Microwave ablation versus other interventions for hepatocellular carcinoma: A systematic review and meta-analysis. *J Cancer Res Ther.* 2020; 16(2): 379-386. PMID 32474527
6. Dou Z, Lu F, Ren L, et al. Efficacy and safety of microwave ablation and radiofrequency ablation in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. *Medicine (Baltimore).* Jul 29 2022; 101(30): e29321. PMID 35905207
7. Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. *Cancer.* Apr 15 1999; 85(8): 1694-702. PMID 10223562
8. Shibata T, Limuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. *Radiology.* May 2002; 223(2): 331-7. PMID 11997534
9. Xu HX, Xie XY, Lu MD, et al. Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation. *Clin Radiol.* Jan 2004; 59(1): 53-61. PMID 14697375
10. Lu MD, Xu HX, Xie XY, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. *J Gastroenterol.* Nov 2005; 40(11): 1054-60. PMID 16322950
11. Tanaka K, Shimada H, Nagano Y, et al. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. *Surgery.* Feb 2006; 139(2): 263-73. PMID 16455336
12. Wang ZL, Liang P, Dong BW, et al. Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. *J Gastrointest Surg.* Feb 2008; 12(2): 327-37. PMID 17943391
13. Ohmoto K, Yoshioka N, Tomiyama Y, et al. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. *J Gastroenterol Hepatol.* Feb 2009; 24(2): 223-7. PMID 18823439
14. Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. *Cancer.* May 01 2009; 115(9): 1914-23. PMID 19241423
15. Kuang M, Xie XY, Huang C, et al. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. *J Gastrointest Surg.* Dec 2011; 15(12): 2165-71. PMID 21972056
16. Imura S, Shimada M, Utsunomiya T, et al. Ultrasound-guided microwave coagulation assists anatomical hepatic resection. *Surg Today.* Jan 2012; 42(1): 35-40. PMID 22075665
17. Qian GJ, Wang N, Shen Q, et al. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. *Eur Radiol.* Sep 2012; 22(9): 1983-90. PMID 22544225
18. Chinnaratha MA, Sathananthan D, Pateria P, Tse E, MacQuillan G, Wigg AJ. Predictors of hepatocellular carcinoma recurrence post thermal ablation. *J Gastroenterol Hepatol.* 2013;28(Suppl. 2):66-67.
19. Ding J, Jing X, Liu J, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. *Eur J Radiol.* Sep 2013; 82(9): 1379-84. PMID 23726122
20. Stättner S, Jones RP, Yip VS, et al. Microwave ablation with or without resection for colorectal liver metastases. *Eur J Surg Oncol.* Aug 2013; 39(8): 844-9. PMID 23769976



21. Takami Y, Ryu T, Wada Y, et al. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. *J Hepatobiliary Pancreat Sci.* Mar 2013; 20(3): 332-41. PMID 22710886
22. Zhang L, Wang N, Shen Q, et al. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. *PLoS One.* 2013; 8(10): e76119. PMID 24146824
23. Abdelaziz A, Elbaz T, Shousha HI, et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. *Surg Endosc.* Dec 2014; 28(12): 3429-34. PMID 24935203
24. Shi J, Sun Q, Wang Y, et al. Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. *J Gastroenterol Hepatol.* 2014; 29(7): 1500-7. PMID 24628534
25. Tan K, DU X, Yin J, et al. Microwave tissue coagulation technique in anatomical liver resection. *Biomed Rep.* Mar 2014; 2(2): 177-182. PMID 24649092
26. Zhang NN, Cheng XJ, Liu JY. Comparison of high-powered MWA and RFA in treating larger hepatocellular carcinoma. *J Pract Oncol.* 2014;29:349-356.
27. Abdelaziz AO, Nabeel MM, Elbaz TM, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. *Scand J Gastroenterol.* Apr 2015; 50(4): 479-84. PMID 25592058
28. Vogl TJ, Farshid P, Naguib NN, et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. *Abdom Imaging.* Aug 2015; 40(6): 1829-37. PMID 25601438
29. Xu J, Zhao Y. Comparison of percutaneous microwave ablation and laparoscopic resection in the prognosis of liver cancer. *Int J Clin Exp Pathol.* 2015; 8(9): 11665-9. PMID 26617907
30. Potretzke TA, Ziemlewicz TJ, Hinshaw JL, et al. Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center. *J Vasc Interv Radiol.* May 2016; 27(5): 631-8. PMID 27017124
31. Zhang EL, Yang F, Wu ZB, et al. Therapeutic efficacy of percutaneous microwave coagulation versus liver resection for single hepatocellular carcinoma  $\leq 3$  cm with Child-Pugh A cirrhosis. *Eur J Surg Oncol.* May 2016; 42(5): 690-7. PMID 26995115
32. Li W, Zhou X, Huang Z, et al. Short-term and long-term outcomes of laparoscopic hepatectomy, microwave ablation, and open hepatectomy for small hepatocellular carcinoma: a 5-year experience in a single center. *Hepatol Res.* Jun 2017; 47(7): 650-657. PMID 27487979
33. Philips P, Scoggins CR, Rostas JK, et al. Safety and advantages of combined resection and microwave ablation in patients with bilobar hepatic malignancies. *Int J Hyperthermia.* Feb 2017; 33(1): 43-50. PMID 27405728
34. Ryu T, Takami Y, Wada Y, et al. Oncological outcomes after hepatic resection and/or surgical microwave ablation for liver metastasis from gastric cancer. *Asian J Surg.* Jan 2019; 42(1): 100-105. PMID 29254868
35. Song P, Sheng L, Sun Y, et al. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. *Oncotarget.* Aug 01 2017; 8(31): 51792-51799. PMID 28881688
36. Xu Y, Shen Q, Wang N, et al. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. *Chin J Cancer.* Jan 19 2017; 36(1): 14. PMID 28103953
37. Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. *Gut.* Jun 2017; 66(6): 1172-1173. PMID 27884919
38. Zhang QB, Zhang XG, Jiang RD, et al. Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. *Int J Hyperthermia.* May 2017; 33(3): 255-262. PMID 27817240
39. Chen ZB, Qin F, Ye Z, et al. Microwave-assisted liver resection vs. clamp crushing liver resection in cirrhosis patients with hepatocellular carcinoma. *Int J Hyperthermia.* Dec 2018; 34(8): 1359-1366. PMID 29353503





40. Chong CCN, Lee KF, Chu CM, et al. Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. *HPB (Oxford)*. Jun 2018; 20(6): 546-554. PMID 29352659
41. Chinnaratha MA, Sathananthan D, Pateria P, et al. High local recurrence of early-stage hepatocellular carcinoma after percutaneous thermal ablation in routine clinical practice. *Eur J Gastroenterol Hepatol*. Mar 2015; 27(3): 349-54. PMID 25563141
42. Cillo U, Noaro G, Vitale A, et al. Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. *HPB (Oxford)*. Nov 2014; 16(11): 979-86. PMID 24750429
43. Correa-Gallego C, Fong Y, Gonen M, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. *Ann Surg Oncol*. Dec 2014; 21(13): 4278-83. PMID 24889486
44. Di Vece F, Tombesi P, Ermili F, et al. Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: a prospective pilot study. *Cardiovasc Intervent Radiol*. Jun 2014; 37(3): 723-9. PMID 24196263
45. Hompes R, Fieuws S, Aerts R, et al. Results of single-probe microwave ablation of metastatic liver cancer. *Eur J Surg Oncol*. Aug 2010; 36(8): 725-30. PMID 20605397
46. Kamal A, Elmoety AAA, Rostom YAM, et al. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. *J Gastrointest Oncol*. Jun 2019; 10(3): 562-571. PMID 31183208
47. Lee KF, Wong J, Hui JW, et al. Long-term outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma by surgical approach: A retrospective comparative study. *Asian J Surg*. Jul 2017; 40(4): 301-308. PMID 26922631
48. Liu Y, Li S, Wan X, et al. Efficacy and safety of thermal ablation in patients with liver metastases. *Eur J Gastroenterol Hepatol*. Apr 2013; 25(4): 442-6. PMID 23470267
49. Liu W, Zheng Y, He W, et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. *Aliment Pharmacol Ther*. Sep 2018; 48(6): 671-681. PMID 30063081
50. Sakaguchi H, Seki S, Tsuji K, et al. Endoscopic thermal ablation therapies for hepatocellular carcinoma: a multi-center study. *Hepatol Res*. Jan 2009; 39(1): 47-52. PMID 18761680
51. Santambrogio R, Chiang J, Barabino M, et al. Comparison of Laparoscopic Microwave to Radiofrequency Ablation of Small Hepatocellular Carcinoma ( $\leq 3$  cm). *Ann Surg Oncol*. Jan 2017; 24(1): 257-263. PMID 27581608
52. Sever I H, Sucu M, Biyikli E. Radiofrequency and Microwave Ablation in the Treatment of Hepatocellular Carcinoma. *Iran J Radiol*. 2018;15(3):e62396. doi: 10.5812/iranjradiol.62396.
53. Shady W, Petre EN, Do KG, et al. Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. *J Vasc Interv Radiol*. Feb 2018; 29(2): 268-275.e1. PMID 29203394
54. Simo KA, Sereika SE, Newton KN, et al. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: safety and efficacy in comparison with radiofrequency ablation. *J Surg Oncol*. Dec 2011; 104(7): 822-9. PMID 21520094
55. Sparchez Z, Mocan T, Hajjar NA, et al. Percutaneous ultrasound guided radiofrequency and microwave ablation in the treatment of hepatic metastases. A monocentric initial experience. *Med Ultrason*. Aug 31 2019; 21(3): 217-224. PMID 31476199
56. Tian W, Kuang M, Lv M, et al. A randomised comparative trial on liver tumors treated with ultrasound-guided percutaneous radiofrequency versus microwave ablation. *Chin J Hepatobiliary Surg* 2014;20:11922.
57. van Tilborg AA, Scheffer HJ, de Jong MC, et al. MWA Versus RFA for Perivascular and Peribiliary CRLM: A Retrospective Patient- and Lesion-Based Analysis of Two Historical Cohorts. *Cardiovasc Intervent Radiol*. Oct 2016; 39(10): 1438-46. PMID 27387188
58. Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. *Lancet Gastroenterol Hepatol*. May 2018; 3(5): 317-325. PMID 29503247



59. Yang B, Li Y. A comparative study of laparoscopic microwave ablation with laparoscopic radiofrequency ablation for colorectal liver metastasis. *J BUON*. 2017; 22(3): 667-672. PMID 28730772
60. Chong CCN, Lee KF, Cheung SYS, et al. Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial). *HPB (Oxford)*. Aug 2020; 22(8): 1121-1127. PMID 32044268
61. Vogl TJ, Martin SS, Gruber-Rouh T, et al. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial. *Rofo*. May 2024; 196(5): 482-490. PMID 38065541
62. Zaitoun MMA, Elsayed SB, Zaitoun NA, et al. Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma 3- 5 cm. *Int J Hyperthermia*. 2021; 38(1): 248-256. PMID 33615957
63. Loveman E, Jones J, Clegg AJ, et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. *Health Technol Assess*. Jan 2014; 18(7): vii-viii, 1-283. PMID 24484609
64. Bala MM, Riemsma RP, Wolff R, et al. Microwave coagulation for liver metastases. *Cochrane Database Syst Rev*. Oct 13 2013; (10): CD010163. PMID 24122576
65. Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis*. Sep 2011; 13(9): e252-65. PMID 21689362
66. Mimmo A, Pegoraro F, Rhaïem R, et al. Microwave Ablation for Colorectal Liver Metastases: A Systematic Review and Pooled Oncological Analyses. *Cancers (Basel)*. Mar 03 2022; 14(5). PMID 35267612
67. Yuan Z, Wang Y, Zhang J, et al. A Meta-Analysis of Clinical Outcomes After Radiofrequency Ablation and Microwave Ablation for Lung Cancer and Pulmonary Metastases. *J Am Coll Radiol*. Mar 2019; 16(3): 302-314. PMID 30642784
68. Jiang B, McClure MA, Chen T, et al. Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis. *Ann Thorac Med*. 2018; 13(4): 243-250. PMID 30416597
69. Nelson DB, Tam AL, Mitchell KG, et al. Local Recurrence After Microwave Ablation of Lung Malignancies: A Systematic Review. *Ann Thorac Surg*. Jun 2019; 107(6): 1876-1883. PMID 30508527
70. He W, Hu XD, Wu DF, et al. Ultrasonography-guided percutaneous microwave ablation of peripheral lung cancer. *Clin Imaging*. 2006; 30(4): 234-41. PMID 16814137
71. Wolf FJ, Grand DJ, Machan JT, et al. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. *Radiology*. Jun 2008; 247(3): 871-9. PMID 18372457
72. Vogl TJ, Naguib NN, Gruber-Rouh T, et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. *Radiology*. Nov 2011; 261(2): 643-51. PMID 22012906
73. Lu Q, Cao W, Huang L, et al. CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases. *World J Surg Oncol*. May 07 2012; 10: 80. PMID 22564777
74. Carrafiello G, Mangini M, Fontana F, et al. Microwave ablation of lung tumours: single-centre preliminary experience. *Radiol Med*. Jan 2014; 119(1): 75-82. PMID 24234180
75. Liu H, Steinke K. High-powered percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: a preliminary study. *J Med Imaging Radiat Oncol*. Aug 2013; 57(4): 466-74. PMID 23870347
76. Vogl TJ, Worst TS, Naguib NN, et al. Factors influencing local tumor control in patients with neoplastic pulmonary nodules treated with microwave ablation: a risk-factor analysis. *AJR Am J Roentgenol*. Mar 2013; 200(3): 665-72. PMID 23436860
77. Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. *Cardiovasc Intervent Radiol*. Feb 2015; 38(1): 135-42. PMID 24809754
78. Yang X, Ye X, Zheng A, et al. Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases. *J Surg Oncol*. Nov 2014; 110(6): 758-63. PMID 24965604



79. Zheng A, Wang X, Yang X, et al. Major complications after lung microwave ablation: a single-center experience on 204 sessions. *Ann Thorac Surg.* Jul 2014; 98(1): 243-8. PMID 24793688
80. Acksteiner C, Steinke K. Percutaneous microwave ablation for early-stage non-small cell lung cancer (NSCLC) in the elderly: a promising outlook. *J Med Imaging Radiat Oncol.* Feb 2015; 59(1): 82-90. PMID 25335916
81. Wei Z, Ye X, Yang X, et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. *Med Oncol.* Feb 2015; 32(2): 464. PMID 25572816
82. Egashira Y, Singh S, Bandula S, et al. Percutaneous High-Energy Microwave Ablation for the Treatment of Pulmonary Tumors: A Retrospective Single-Center Experience. *J Vasc Interv Radiol.* Apr 2016; 27(4): 474-9. PMID 26944360
83. Ko WC, Lee YF, Chen YC, et al. CT-guided percutaneous microwave ablation of pulmonary malignant tumors. *J Thorac Dis.* Oct 2016; 8(Suppl 9): S659-S665. PMID 28066666
84. Li B, Wang Z, Zhou K, et al. Safety and feasibility within 24 h of discharge in patents with inoperable malignant lung nodules after percutaneous microwave ablation. *J Cancer Res Ther.* Dec 2016; 12(Supplement): C171-C175. PMID 28230012
85. Macchi M, Belfiore MP, Floridi C, et al. Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial. *Med Oncol.* May 2017; 34(5): 96. PMID 28417355
86. Maxwell AW, Healey TT, Dupuy DE. Percutaneous Thermal Ablation for Small-Cell Lung Cancer: Initial Experience with Ten Tumors in Nine Patients. *J Vasc Interv Radiol.* Dec 2016; 27(12): 1815-1821. PMID 27776982
87. Vogl TJ, Eckert R, Naguib NN, et al. Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation. *AJR Am J Roentgenol.* Dec 2016; 207(6): 1340-1349. PMID 27680945
88. Zheng A, Ye X, Yang X, et al. Local Efficacy and Survival after Microwave Ablation of Lung Tumors: A Retrospective Study in 183 Patients. *J Vasc Interv Radiol.* Dec 2016; 27(12): 1806-1814. PMID 27789077
89. Healey TT, March BT, Baird G, et al. Microwave Ablation for Lung Neoplasms: A Retrospective Analysis of Long-Term Results. *J Vasc Interv Radiol.* Feb 2017; 28(2): 206-211. PMID 27993505
90. Nour-Eldin NA, Exner S, Al-Subhi M, et al. Ablation therapy of non-colorectal cancer lung metastases: retrospective analysis of tumour response post-laser-induced interstitial thermotherapy (LITT), radiofrequency ablation (RFA) and microwave ablation (MWA). *Int J Hyperthermia.* Nov 2017; 33(7): 820-829. PMID 28540791
91. Wei Z, Ye X, Yang X, et al. Advanced non small cell lung cancer: response to microwave ablation and EGFR Status. *Eur Radiol.* Apr 2017; 27(4): 1685-1694. PMID 27436020
92. Yang X, Ye X, Huang G, et al. Repeated percutaneous microwave ablation for local recurrence of inoperable Stage I nonsmall cell lung cancer. *J Cancer Res Ther.* 2017; 13(4): 683-688. PMID 28901314
93. Zhong L, Sun S, Shi J, et al. Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation. *J Thorac Dis.* Mar 2017; 9(3): 590-597. PMID 28449467
94. Uhlig J, Strauss A, R cker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. *Eur Radiol.* Mar 2019; 29(3): 1293-1307. PMID 30255245
95. Guan W, Bai J, Liu J, et al. Microwave ablation versus partial nephrectomy for small renal tumors: intermediate-term results. *J Surg Oncol.* Sep 01 2012; 106(3): 316-21. PMID 22488716
96. Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. *Cardiovasc Intervent Radiol.* Apr 2014; 37(2): 427-37. PMID 24482030
97. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome?. *Diagn Interv Radiol.* 2013; 19(6): 501-7. PMID 24084196
98. McClure T, Lansing A, Ferko N, et al. A Comparison of Microwave Ablation and Cryoablation for the Treatment of Renal Cell Carcinoma: A Systematic Literature Review and Meta-analysis. *Urology.* Oct 2023; 180: 1-8. PMID 37331485



99. Guo J, Arellano RS. Percutaneous Microwave Ablation of Category T1a Renal Cell Carcinoma: Intermediate Results on Safety, Technical Feasibility, and Clinical Outcomes of 119 Tumors. *AJR Am J Roentgenol.* Jan 2021; 216(1): 117-124. PMID 32603227
100. Aarts BM, Prevoe W, Meier MAJ, et al. Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma. *Cardiovasc Intervent Radiol.* Jul 2020; 43(7): 1025-1033. PMID 32052093
101. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. *Eur J Surg Oncol.* Dec 2010; 36(12): 1149-55. PMID 20889281
102. Zhou W, Zha X, Liu X, et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study. *Radiology.* May 2012; 263(2): 364-73. PMID 22438362
103. Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. *World J Gastroenterol.* Mar 07 2014; 20(9): 2267-78. PMID 24605026
104. Cui T, Jin C, Jiao D, et al. Safety and efficacy of microwave ablation for benign thyroid nodules and papillary thyroid microcarcinomas: A systematic review and meta-analysis. *Eur J Radiol.* Sep 2019; 118: 58-64. PMID 31439259
105. Wu X, Jiang Z, Liu J, et al. The efficacy and safety of microwave ablation versus conventional open surgery for the treatment of papillary thyroid microcarcinoma: a systematic review and meta-analysis. *Gland Surg.* Jun 2022; 11(6): 1003-1014. PMID 35800741
106. Li X, Fan W, Zhang L, et al. CT-guided percutaneous microwave ablation of adrenal malignant carcinoma: preliminary results. *Cancer.* Nov 15 2011; 117(22): 5182-8. PMID 21523760
107. Pusceddu C, Sotgia B, Fele RM, et al. Treatment of bone metastases with microwave thermal ablation. *J Vasc Interv Radiol.* Feb 2013; 24(2): 229-33. PMID 23200605
108. Yu MA, Liang P, Yu XL, et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. *Eur J Radiol.* Nov 2011; 80(2): 548-52. PMID 21300500
109. Egorov AV, Vasilyev IA, Musayev GH, et al. The role of microwave ablation in management of functioning pancreatic neuroendocrine tumors. *Gland Surg.* Dec 2019; 8(6): 766-772. PMID 32042685
110. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* May 2013; 143(5 Suppl): e278S-e313S. PMID 23649443
111. Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. *J Urol.* Aug 2021; 206(2): 199-208. PMID 34115547
112. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hepatocellular Carcinoma. Version 2.2024. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514>. Accessed November 7, 2024.
113. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed November 7, 2024.
114. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 3.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf). Accessed November 7, 2024.
115. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/neuroendocrine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf). Accessed November 7, 2024.
116. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 1.2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf). Accessed November 7, 2024.
117. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed November 7, 2024.
118. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Cancer. Version 3.2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf). Accessed November 7, 2024.



119. National Institute for Health and Care Excellence (NICE). Microwave ablation for treating liver metastases [IPG553]. 2016; <https://www.nice.org.uk/guidance/ipg553>. Accessed November 7, 2024.
120. National Institute for Health and Care Excellence (NICE). Microwave Ablation of Hepatocellular Carcinoma [IPG214]. 2007; <https://www.nice.org.uk/guidance/ipg214>. Accessed November 7, 2024.
121. National Institute for Health and Care Excellence (NICE). Microwave ablation for treating primary lung cancer and metastases in the lung [IPG469]. 2022; <https://www.nice.org.uk/guidance/ipg716>. Accessed November 7, 2024.
122. Ceppa EP, Collings AT, Abdalla M, et al. SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm. Surg Endosc. Dec 2023; 37(12): 8991-9000. PMID 37957297

## History

Date	Comments
02/27/12	New Policy – Add to Surgery section. Policy created with literature review through October 2011; investigational for all tumors.
07/31/12	Code 47379 added to the policy as this procedure can be performed laparoscopically
09/07/12	Update coding section – ICD-10 codes are now effective 10/01/14.
12/20/12	Update Related Policies; policy number 7.01.540 was replaced with 7.01.95.
04/16/13	Replace policy. Policy updated with literature review; reference numbers 2, 12-13, 21-25, 32 and 36 added. Policy statement unchanged.
12/09/13	Replace policy. Policy Guidelines reformatted for readability. Rationale updated with literature review through August 2013. References 10, 11, 20, 34 added; others renumbered/removed. Policy statement unchanged.
03/11/14	Coding Update. Code 55.33 was removed per ICD-10 mapping project; this code is not utilized for adjudication of policy.
12/17/14	Annual Review. Policy updated with literature review through September 15, 2014, reference numbers 17-18, 29 and 31 added. Reference 46 updated. Policy statement unchanged. ICD-9 and ICD-10 diagnosis and procedure codes removed; these do not relate to policy adjudication.
12/08/15	Annual Review. Policy updated with literature search; no change to the policy statement.
06/01/16	Annual Review, approved May 10, 2016. Policy updated with literature review through February 15, 2016; references added. Clinical input added. Policy statement unchanged. CPT code 0301T added to this policy.
11/01/17	Annual Review, approved October 19, 2017. Policy updated with literature review through July 20, 2017; no references added, references 44 and 47 updated. Policy statement unchanged. Removed CPT code 47379. Added CPT codes 32999 and 49999.



Date	Comments
12/01/18	Annual Review, approved November 6, 2018. Policy updated with literature review through July 2018; no references added, references 42-43 updated. Policy statement unchanged. Added termination date 1/1/2018 for CPT 0301T.
01/01/19	Coding update, removed 0301T as it was terminated 1/1/18.
12/01/19	Annual Review, approved November 12, 2019. Policy updated with literature review through July 2019; references added. Policy statements changed to medically necessary for lung and liver tumors; statements for other tumor types unchanged.
06/30/2020	Coding update. Removed CPT codes 19499, 32999, 47399, 49999, 50592, 53899 and 76940.
08/01/20	Update Related Policies. 8.01.521 is now 8.01.43.
11/01/20	Coding update. Added HCPCS code C9751.
01/01/21	Annual Review, approved December 1, 2020. Policy updated with literature review through September 28, 2020; references added. Policy statements unchanged. Added CPT code 50592.
01/01/22	Annual Review, approved December 2, 2021. Policy updated with literature review through August 19, 2021; references added. Policy statements unchanged.
01/01/23	Annual Review, approved December 12, 2022. Policy updated with literature review through August 30, 2022; references added. Policy statements unchanged. Changed the wording from "patient" to "individual" throughout the policy for standardization.
06/15/23	Update to Related Policies. 8.01.43 is replaced with 8.01.521 Radioembolization for Primary and Metastatic Tumors of the Liver.
01/01/24	Annual Review, approved December 11, 2023. Policy updated with literature review through August 25, 2023; references added. Policy statements unchanged.
01/01/25	Annual Review, approved December 9, 2024. Policy updated with literature review through August 13, 2024; references added. Policy statements unchanged. Added new CPT code 0944T.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2025 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member



benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

